News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides a brief "Q2 Earnings Snapshot" for Aquestive Therapeutics. It is a very short piece, indicating that the company's Q2 earnings were reported.
Aquestive Therapeutics plans to resubmit its drug application for Anaphylm, an oral dissolving film for severe allergic reactions, to the FDA this fall. This follows the completion of two additional studies requested by the FDA, which have yielded positive results regarding revised packaging, ease …
Aquestive Therapeutics (NASDAQ:AQST) saw its shares rise 7.1% to $4.595, with a market capitalization of approximately $574 million. The company's stock holds a consensus "Buy" rating from analysts with an average price target of $8.50, driven by its recent beat on quarterly earnings expectations. …
HireQuest (NASDAQ: HQI), a staffing and recruiting services franchisor, reported a 6% year-over-year increase in Q2 revenue, reaching $8.1 million, driven by an industry recovery. The company's net income soared by 154% to $2.7 million, largely due to a significant decrease in administrative expenses. …
HireQuest reported a significant increase in profitability for Q2 2026, with diluted EPS rising to $0.19 and net income more than doubling, primarily driven by a 31.9% reduction in SG&A expenses. Despite a reported decline in system-wide sales due to the MRINetwork divestiture, the …
HireQuest (HQI) reported significantly increased profitability for Q2 and the first half of 2026, with net income more than doubling in Q2 and Adjusted EBITDA also seeing substantial growth. This improved performance occurred despite a modest revenue decrease year-to-date, primarily due to lower operating …
HireQuest, Inc. (HQI) reported its second-quarter 2026 results, showing a 6% increase in revenue to $8.1M and a diluted EPS of $0.19, significantly up from $0.08 in the prior year. Net income rose by 154% to $2.69M. The revenue growth was primarily driven by …
Aquestive Therapeutics announced positive topline results from its human factors and pharmacokinetic studies for Anaphylm™ sublingual film, an epinephrine product for severe allergic reactions. These results support the planned resubmission of its New Drug Application (NDA) to the FDA in the third quarter of …
Tutor Perini, AAON, Onterris, Quest Resource, and Blink Charging Shares Skyrocket, What You Need To Know What Happened? A number of stocks jumped in the after-market session after the July jobs report showed an unexpected loss of 23,000 jobs, signaling a cooling labor market. …
HireQuest reported stronger-than-expected Q2 2026 results, with diluted EPS of $0.19 and revenue of $8.1 million, marking its first year-over-year revenue growth since Q3 2024. The company's stock rose significantly, trading near its 52-week high. Management expressed optimism for the rest of 2026, citing …
The provided content is not an article but rather a privacy notice or a placeholder. It does not contain any information about Insight Molecular Diagnostics or its Q2 earnings. Therefore, no meaningful summary can be generated.
HireQuest Inc (HQI) is scheduled to release its Q2 2026 earnings on August 10, 2026, with revenue estimated at $7.08 million and earnings at $0.14 per share. While analyst price targets suggest an upside of 16.26%, GuruFocus's GF Value indicates a 19.09% downside. Revenue …
Aquestive Therapeutics (AQST) announced positive results from human factors and pharmacokinetic validation studies for its Anaphylm sublingual film, a severe allergy treatment. These studies address prior FDA feedback, demonstrating significant improvements in product usability and effective drug delivery even with slight misplacement. The company …
Aquestive Therapeutics Inc (AQST) is preparing to release its Q2 2026 earnings on August 11, 2026, with revenue expected at $11.42 million and earnings at $-0.12 per share. While analysts predict a significant upside of 125.61% based on average price targets, GuruFocus's GF Value …
Aquestive Therapeutics has announced positive topline results from its human factors and pharmacokinetic studies for Anaphylm™ (dibutepinephrine) sublingual film. These results support the planned resubmission of its New Drug Application (NDA) to the FDA in Q3 2026, addressing previous issues with packaging and administration. …
Aquestive Therapeutics has released supplemental materials on human factors and clinical results for its Anaphylm (dibutepinephrine) sublingual film program. A resubmission human factors study showed fewer use issues compared to the original NDA study, with a median open time reduced to 3 seconds. A …
Aquestive announced positive human factors and pharmacokinetic (PK) results for Anaphylm, indicating significant improvements in usability and comparable drug delivery. These results support the planned New Drug Application (NDA) resubmission in Q3 2026 for the epinephrine treatment. The study showed reduced errors in self-administration …
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and its officers. The lawsuit, filed on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026, alleges that the company made false …
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. (AQST) who bought securities prior to June 16, 2025, and still hold them. The investigation aims to determine if Aquestive officers engaged in corporate wrongdoing. The firm …
This article details IVY LANE CAPITAL MANAGEMENT, LLC's historical holdings in Quest Diagnostics Inc (DGX). As of March 31, 2026, the firm holds 29,000 shares valued at $5.68 million, representing 8.59% of its portfolio. The investment has generated an estimated gain of $4.19 million, …
This article provides a brief update on Quest Resource Holding Corp (QRHC) stock news, earnings, analyst ratings, and key developments. It notes that more news is expected soon and provides current stock performance data, showing a recent increase of 18.11%. The page serves as …
This article provides an earnings forecast for Quest Resource Holding Corp (QRHC), highlighting its current earnings forecast score, average price target of $3.00, and analyst ratings. Based on 2 analysts, the stock has a "Buy" trend. Key financial expectations include an anticipated revenue of …
This article from TradingKey provides a news page for Quest Diagnostics Inc (DGX) stock. It includes current stock performance metrics like price, market cap, and P/E ratio. The page indicates that more news will be coming soon regarding DGX stock.
Search by ticker symbol or company name and select a result to open its chart.